Cytoagents, Inc

100 S Commons Ste 102
Pittsburgh, PA 15212

CytoAgents, Inc is a Pittsburgh-based biotechnology company that is dedicated to developing innovative treatments for Cytokine Release Syndrome (CRS), a potentially life-threatening immune system overreaction. Their lead therapy, CTO1681, is an orally bioavailable immunomodulator that safely downregulates the production of CRS-inducing cytokines, effectively stopping CRS and rebalancing the body's immune response.

With a highly specific mechanism of action and demonstrated efficacy in multiple models, CytoAgents is currently conducting a Phase 1b/2a clinical trial to treat CRS in patients receiving CAR T-cell therapy. Their goal is to provide a safe and effective treatment for CRS, improving patient outcomes and expanding access to important new treatment modalities in oncology and other therapeutic areas.

Generated from the website

Own this business?
See a problem?

You might also like

United StatesPennsylvaniaPittsburghCytoagents, Inc

Partial Data by Infogroup (c) 2025. All rights reserved.